Short Interest in Lunai Bioworks Inc. (NASDAQ:LNAI) Drops By 86.1%

Lunai Bioworks Inc. (NASDAQ:LNAI) was the target of a significant decline in short interest in the month of May. As of May 29th, there was short interest totaling 345,109 shares, a decline of 86.1% from the May 14th total of 2,489,634 shares. Currently, 7.7% of the company’s shares are short sold. Based on an average daily trading volume, of 217,022 shares, the short-interest ratio is currently 1.6 days.

Institutional Trading of Lunai Bioworks

A hedge fund recently bought a new stake in Lunai Bioworks stock. Millennium Management LLC purchased a new position in Lunai Bioworks Inc. (NASDAQ:LNAI) during the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm purchased 202,629 shares of the company’s stock, valued at approximately $288,000. Millennium Management LLC owned about 0.87% of Lunai Bioworks as of its most recent SEC filing. Institutional investors own 71.41% of the company’s stock.

Analysts Set New Price Targets

LNAI has been the topic of several recent analyst reports. Weiss Ratings reiterated a “sell (e+)” rating on shares of Lunai Bioworks in a report on Friday, April 10th. Wall Street Zen upgraded shares of Lunai Bioworks to a “sell” rating in a report on Saturday, May 23rd. One equities research analyst has rated the stock with a Sell rating, Based on data from MarketBeat, Lunai Bioworks currently has an average rating of “Sell”.

Lunai Bioworks Stock Performance

Shares of LNAI stock opened at $2.50 on Friday. Lunai Bioworks has a 52-week low of $1.21 and a 52-week high of $33.50. The company has a 50-day simple moving average of $2.60 and a two-hundred day simple moving average of $4.96. The company has a market capitalization of $11.33 million, a price-to-earnings ratio of -6.25 and a beta of 0.40.

Lunai Bioworks (NASDAQ:LNAI) last issued its quarterly earnings data on Friday, May 15th. The company reported ($0.80) earnings per share (EPS) for the quarter. The business had revenue of $0.02 million for the quarter.

Lunai Bioworks Company Profile

Enochian Biosciences, Inc, a pre-clinical stage biotechnology company, engages in the research and development of pharmaceutical and biological products for the human treatment of human immunodeficiency virus (HIV), hepatitis B virus (HBV), influenza and coronavirus infections, and cancer. The company’s lead candidate includes ENOB-HV-01 for autologous HIV curative treatment; ENOB-HV-11, a preventative HIV vaccine; ENOB-HV-12, a therapeutic HIV vaccine; and ENOB-HB-01, a coopting HBV polymerase. Its pipeline development products comprise ENOB-DC-11 off the shelf DC vaccine for multiple solid tumors; and ENOB-DC-21, a non-specific vaccine for intraturmoral injection.